Repro Med Systems, Inc. Qualifies To Trade On OTCQX Market

CHESTER, NY / ACCESSWIRE / September 18, 2015 / Repro Med Systems, Inc., dba RMS Medical Products (OTCQX: REPR), a manufacturer of medical devices for the ambulatory (home and institution) infusion market, has qualified to trade on the OTCQX(R) Best Market. Repro Med begins trading today on OTCQX under the symbol “REPR.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

R. Cromwell Coulson, President and CEO of OTC Markets Group, said, “We are pleased to welcome Repro Med to the family of established, global and growth companies on our OTCQX market,” “OTCQX provides a transparent public trading market for growing companies like Repro Med that are committed to maintaining high-quality financial and operating standards. We look forward to supporting Repro Med in its continued growth as a publicly-traded company.”

In addition to meeting high financial and disclosure standards, OTCQX U.S. companies must be sponsored by an approved third-party investment bank or law firm called a Designated Advisor For Disclosure (“DAD”). Salon Marrow Dyckman Newman & Broudy LLP serves as Repro Med’s DAD on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.

Andrew Sealfon, President of RMS, commented, “Our focus on building our core business is bearing gratifying results in building value for our shareholders. Qualifying for trading on OTCQX is an important step in fulfilling our commitments to transparency and compliance. It is also an important foundation for executing our long term strategy for product line expansion and profitable sales growth.”

About Repro Med Systems, Inc.

Repro Med designs, manufactures and markets proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications for domestic and international markets.

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes”, “belief”, “expects”, “intends”, “anticipates”, “will”, or “plans” to be uncertain and forward looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company’s reports and registration statements filed with the Securities and Exchange Commission.

For more information please call:

Mike King
702-650-3000
Princeton Research

SOURCE: Repro-Med Systems, Inc.

ReleaseID: 432068